Is there such a thing as the “right” timing?

A ‘one size fits all’ approach to the timing and methodology of appraisals will fail to take account of the complexity of conducting assessments and would ignore differences in diseases, treatments, and patient populations.  Often the sort of data needed to confirm cost- and clinical effectiveness, and efficiency is data on real-life clinical use of an intervention.  The data can only be collected once the intervention is on the market for some time, and will depend on prevalence.  Manufacturers should therefore be able to submit health outcomes information to the relevant government bodies throughout a product’s lifecycle.  This evidence should receive appropriate attention and reward from payers.